Abstract
CD9 has been shown to be differentially expressed in childhood TEL/AML1-positive acute lymphoblastic leukemia (ALL). We confirmed this finding in large Affymetrix data sets and in 80 new cases at both RNA and protein levels. Moreover, we showed that mean fluorescence intensity of CD9 by flow cytometry can distinguish TEL/AML1-positive ALL from other BCP-ALL. Using ROC analysis, the most efficient model for predicting TEL/AML1-positive ALL combined CD9 (mean fluorescence intensity <or=20) and CD10 values (positive cells >40%). Finally, we propose a faster procedure for optimizing the diagnosis of childhood BCP-ALL subgroups.
Copyright (c) 2009 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Validation Study
MeSH terms
-
Algorithms
-
Antigens, CD / genetics*
-
Antigens, CD / metabolism
-
Biomarkers, Tumor / analysis
-
Biomarkers, Tumor / genetics
-
Child
-
Core Binding Factor Alpha 2 Subunit / analysis
-
Core Binding Factor Alpha 2 Subunit / genetics*
-
Decision Support Techniques*
-
False Positive Reactions
-
Gene Expression Profiling
-
Gene Expression Regulation, Leukemic
-
Humans
-
Membrane Glycoproteins / genetics*
-
Membrane Glycoproteins / metabolism
-
Oligonucleotide Array Sequence Analysis
-
Oncogene Proteins, Fusion / analysis
-
Oncogene Proteins, Fusion / genetics*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
-
Prognosis
-
Tetraspanin 29
-
Time Factors
-
Tumor Cells, Cultured
Substances
-
Antigens, CD
-
Biomarkers, Tumor
-
CD9 protein, human
-
Core Binding Factor Alpha 2 Subunit
-
Membrane Glycoproteins
-
Oncogene Proteins, Fusion
-
TEL-AML1 fusion protein
-
Tetraspanin 29